These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

202 related articles for article (PubMed ID: 25368674)

  • 41. IL-17E synergizes with EGF and confers in vitro resistance to EGFR-targeted therapies in TNBC cells.
    Merrouche Y; Fabre J; Cure H; Garbar C; Fuselier C; Bastid J; Antonicelli F; Al-Daccak R; Bensussan A; Giustiniani J
    Oncotarget; 2016 Aug; 7(33):53350-53361. PubMed ID: 27462789
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Anti-EGFR monoclonal antibodies enhance sensitivity to DNA-damaging agents in BRCA1-mutated and PTEN-wild-type triple-negative breast cancer cells.
    El Guerrab A; Bamdad M; Bignon YJ; Penault-Llorca F; Aubel C
    Mol Carcinog; 2017 May; 56(5):1383-1394. PubMed ID: 27864890
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Ad-p53 enhances the sensitivity of triple-negative breast cancer MDA-MB-468 cells to the EGFR inhibitor gefitinib.
    Wang X; Song H; Yu Q; Liu Q; Wang L; Liu Z; Yu Z
    Oncol Rep; 2015 Feb; 33(2):526-32. PubMed ID: 25501339
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Targeting of PYK2 Synergizes with EGFR Antagonists in Basal-like TNBC and Circumvents HER3-Associated Resistance via the NEDD4-NDRG1 Axis.
    Verma N; Müller AK; Kothari C; Panayotopoulou E; Kedan A; Selitrennik M; Mills GB; Nguyen LK; Shin S; Karn T; Holtrich U; Lev S
    Cancer Res; 2017 Jan; 77(1):86-99. PubMed ID: 27793840
    [TBL] [Abstract][Full Text] [Related]  

  • 45. EGFR signaling promotes resistance to CHK1 inhibitor prexasertib in triple negative breast cancer.
    Lee KJ; Wright G; Bryant H; Wiggins LA; Schuler M; Gassman NR
    Cancer Drug Resist; 2020; 3(4):980-991. PubMed ID: 35582228
    [No Abstract]   [Full Text] [Related]  

  • 46. ErbB-inhibitory protein: a modified ectodomain of epidermal growth factor receptor synergizes with dasatinib to inhibit growth of breast cancer cells.
    Nautiyal J; Yu Y; Aboukameel A; Kanwar SS; Das JK; Du J; Patel BB; Sarkar FH; Rishi AK; Mohammad RM; Majumdar AP
    Mol Cancer Ther; 2010 Jun; 9(6):1503-14. PubMed ID: 20515951
    [TBL] [Abstract][Full Text] [Related]  

  • 47. CIP2A is a target of bortezomib in human triple negative breast cancer cells.
    Tseng LM; Liu CY; Chang KC; Chu PY; Shiau CW; Chen KF
    Breast Cancer Res; 2012 Apr; 14(2):R68. PubMed ID: 22537901
    [TBL] [Abstract][Full Text] [Related]  

  • 48. The scaffolding protein NHERF1 sensitizes EGFR-dependent tumor growth, motility and invadopodia function to gefitinib treatment in breast cancer cells.
    Bellizzi A; Greco MR; Rubino R; Paradiso A; Forciniti S; Zeeberg K; Cardone RA; Reshkin SJ
    Int J Oncol; 2015 Mar; 46(3):1214-24. PubMed ID: 25530180
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Neurokinin-1 activation affects EGFR related signal transduction in triple negative breast cancer.
    Wang JG; Yu J; Hu JL; Yang WL; Ren H; Ding D; Zhang L; Liu XP
    Cell Signal; 2015 Jul; 27(7):1315-24. PubMed ID: 25817575
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Targeting c-Met in triple negative breast cancer: preclinical studies using the c-Met inhibitor, Cpd A.
    Breen L; Gaule PB; Canonici A; Walsh N; Collins DM; Cremona M; Hennessy BT; Duffy MJ; Crown J; Donovan NO; Eustace AJ
    Invest New Drugs; 2020 Oct; 38(5):1365-1372. PubMed ID: 32318883
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Co-targeting EGFR and mTOR with gefitinib and everolimus in triple-negative breast cancer cells.
    El Guerrab A; Bamdad M; Bignon YJ; Penault-Llorca F; Aubel C
    Sci Rep; 2020 Apr; 10(1):6367. PubMed ID: 32286420
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Tumor inhibitory effect of gefitinib (ZD1839, Iressa) and taxane combination therapy in EGFR-overexpressing breast cancer cell lines (MCF7/ADR, MDA-MB-231).
    Takabatake D; Fujita T; Shien T; Kawasaki K; Taira N; Yoshitomi S; Takahashi H; Ishibe Y; Ogasawara Y; Doihara H
    Int J Cancer; 2007 Jan; 120(1):181-8. PubMed ID: 17036319
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Blocking c-Met and EGFR reverses acquired resistance of PARP inhibitors in triple-negative breast cancer.
    Chu YY; Yam C; Chen MK; Chan LC; Xiao M; Wei YK; Yamaguchi H; Lee PC; Han Y; Nie L; Sun X; Moulder SL; Hess KR; Wang B; Hsu JL; Hortobagyi GN; Litton J; Chang JT; Hung MC
    Am J Cancer Res; 2020; 10(2):648-661. PubMed ID: 32195033
    [TBL] [Abstract][Full Text] [Related]  

  • 54. ANXA2 could act as a moderator of EGFR-directed therapy resistance in triple negative breast cancer.
    Zhang Y; Bi J; Zhu H; Shi M; Zeng X
    Biosci Biotechnol Biochem; 2018 Oct; 82(10):1733-1741. PubMed ID: 29912633
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Met kinase inhibitor E7050 reverses three different mechanisms of hepatocyte growth factor-induced tyrosine kinase inhibitor resistance in EGFR mutant lung cancer.
    Wang W; Li Q; Takeuchi S; Yamada T; Koizumi H; Nakamura T; Matsumoto K; Mukaida N; Nishioka Y; Sone S; Nakagawa T; Uenaka T; Yano S
    Clin Cancer Res; 2012 Mar; 18(6):1663-71. PubMed ID: 22317763
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Systems modelling of the EGFR-PYK2-c-Met interaction network predicts and prioritizes synergistic drug combinations for triple-negative breast cancer.
    Shin SY; Müller AK; Verma N; Lev S; Nguyen LK
    PLoS Comput Biol; 2018 Jun; 14(6):e1006192. PubMed ID: 29920512
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Overexpression of miR-361-5p in triple-negative breast cancer (TNBC) inhibits migration and invasion by targeting RQCD1 and inhibiting the EGFR/PI3K/Akt pathway.
    Han J; Yu J; Dai Y; Li J; Guo M; Song J; Zhou X
    Bosn J Basic Med Sci; 2019 Feb; 19(1):52-59. PubMed ID: 29924958
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Metalloprotease-dependent activation of EGFR modulates CD44
    Wise R; Zolkiewska A
    Breast Cancer Res Treat; 2017 Nov; 166(2):421-433. PubMed ID: 28791489
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Increased TGF-α as a mechanism of acquired resistance to the anti-EGFR inhibitor cetuximab through EGFR-MET interaction and activation of MET signaling in colon cancer cells.
    Troiani T; Martinelli E; Napolitano S; Vitagliano D; Ciuffreda LP; Costantino S; Morgillo F; Capasso A; Sforza V; Nappi A; De Palma R; D'Aiuto E; Berrino L; Bianco R; Ciardiello F
    Clin Cancer Res; 2013 Dec; 19(24):6751-65. PubMed ID: 24122793
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Hepatocyte growth factor induces resistance to anti-epidermal growth factor receptor antibody in lung cancer.
    Yamada T; Takeuchi S; Kita K; Bando H; Nakamura T; Matsumoto K; Yano S
    J Thorac Oncol; 2012 Feb; 7(2):272-80. PubMed ID: 22089117
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.